​

Rein Therapeutics Stock (NASDAQ:RNTX)

OwnershipFinancialsChart
Rein Therapeutics by TradingView

Previous Close

$0.92

52W Range

$0.89 - $2.18

50D Avg

$1.27

200D Avg

$1.29

Market Cap

$25.88M

Avg Vol (3M)

$630.90K

Beta

1.35

Div Yield

-

RNTX Company Profile

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Jun 29, 2017

Website

RNTX Performance

RNTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-50.63M$-65.11M$-16.28K
Net Income$-49.87M$-62.88M$-15.73K
EBITDA$-50.63M$-28.05M$-15.23K
Basic EPS$-1.96$-3.51$-3.42
Diluted EPS$-1.96$-3.51$-3.42

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 19Nov 10, 19 | 2:26 AM

Peer Comparison

TickerCompany
NOTVInotiv, Inc.
KZRKezar Life Sciences, Inc.
MRSNMersana Therapeutics, Inc.
YI111, Inc.
CELUCelularity Inc.
TPSTTempest Therapeutics, Inc.
BEATHeartBeam, Inc.
BCABBioAtla, Inc.
QNTMQuantum BioPharma Ltd.